WP Peptide LR
Whitmania pigra-derived anticoagulant peptide showing neuroprotection in rat MCAO ischemia-reperfusion model (Liu 2026) — thrombin modulation + fibrinolysis homeostasis.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Whitmania pigra-derived anticoagulant peptide showing neuroprotection in rat MCAO ischemia-reperfusion model (Liu 2026) — thrombin modulation + fibrinolysis homeostasis.
- Evidence level
- Preclinical (animal)
- Drug vs leech
- Synthetic analog
- Safety domains
- Bleeding
Clinical translation limit
LR peptide's neuroprotection in rat MCAO does NOT establish clinical efficacy in human ischemic stroke. No FDA-approved derivative exists; numerous animal-model stroke neuroprotectants have failed in human RCTs.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 600 Da
- Source species
- Whitmania pigra
- Discovered
- 2026 · Liu R et al.
Biological Targets
- → thrombin / coagulation-fibrinolysis homeostasis (rat MCAO model)
Key Citations
- Liu R et al. (2026), Brain Res · PMID 41765218
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.